JAX-CKB: #PrecisionMedicine platform by @jacksonlab for interpreting human #cancer variants, #genomics & #proteomics, to match to therapies and #clinicaltrials.
Joined June 2017
- Tweets573
- Following4.2K
- Followers1.1K
- Likes458
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Early results from phase I ARROS-1 trial: NVL-520 in #ROS1 by Dr. @alexdrilon at #ENA2022. This novel ROS1 inhibitor is designed to avoid #NTRK (and TRK-related toxicities, which often limit dose intensity). Studied in a heavily pretreated population (71% with ≥2 TKIs and chemo)
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Check out our new publication: Remotely Guided Immunobots Engaged in Anti-Tumorigenic Phenotypes for Targeted Cancer Immunotherapy- where we convert live macrophages into robots for targeted immunoengineering.
onlinelibrary.wiley.com/doi/…
@NihalOlcay @metin_sitti @MayoClinic @MPI_IS
JAX Clinical Knowledgebase (JAX-CKB) retweeted
"Scientists are developing numerous approaches to make [cancer] immunotherapy safer, including drafting different immune cells, like the awesomely-named natural killer cells.
Another option is Calibr’s off switch."
freethink.com/health/switcha…
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22
✅Luminal A/B subtypes enriched in HER2Low vs HER2-0
✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression
✅New diagnostic assays (mRNA?) needed
@OncoAlert
@myESMO
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Looking forward to chairing this study with @MeghnaTrivedi3 and working with my @jacksonlab colleagues in @JAXClinicalEd and @JAX_CKB
Do more #CancerPatients get genome-informed #cancer treatment when a genomic tumor board helps doctors choose treatments? Study S2108CD is designed to answer this question. Learn more at SWOG.org/S2108CD. Or call 1-800-4-CANCER. Ask about S2108CD. #bcsm #LCSM #CRCSM
JAX Clinical Knowledgebase (JAX-CKB) retweeted
The concept of Temozolomide induced hypermutation causing sensitivity towards #Immunotherapy fascinates me
A case report in @ASCO @JCOPO_ASCO describes successful ICI treatment of an atypical carcinoid tumour after TMZ.
#@OncoAlert 🚨#PrecisionMedicine
ascopubs.org/doi/pdf/10.1200… – at San Vincenzo, Tuscany
JAX Clinical Knowledgebase (JAX-CKB) retweeted
It’s out! We identify mutual exclusivity between microsatellite instability and HRD. BRCA1/2 mutations in MSI-H tumors are predominantly monoallelic passenger alterations which may not predict PARPi sensitivity. Rather patients may benefit from ICI. ascopubs.org/doi/abs/10.1200…
JAX Clinical Knowledgebase (JAX-CKB) retweeted
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemo results in longer event-free survival and a greater likelihood of pathological complete response than chemo alone. #AACR22 nej.md/3DH1I1y
JAX Clinical Knowledgebase (JAX-CKB) retweeted
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma janssen.com/us-fda-approves-…
JAX Clinical Knowledgebase (JAX-CKB) retweeted
🆕 @ASCO #ASCODailyNews ✍🏽
🧬#ctDNA Assays: Exploring Their Clinical Use in Oncology Care
dailynews.ascopubs.org/do/10…
💡👏🏾Let’s explore how these #LiquidBiopsies are being incorporated into every phase of #cancer continuum.🔬🩸
#PrecisionMedicine #OncoAlert #MedTwitter #Genomics – at Manhattan, NY
JAX Clinical Knowledgebase (JAX-CKB) retweeted
#JCOPO study showing that TMB is associated w/ the primary site of #melanoma according to sun exposure, which in turn is a biomarker of response to immune checkpoint inhibitors ☀️ fal.cn/3l8uE #melsm
JAX Clinical Knowledgebase (JAX-CKB) retweeted
ERK1/2 phosphorylation on IHC is associated with tumour-infiltrating myeloid cell/microglia with elevated expression of MHC class II & associated genes, & was predictive of OS following PD-1 blockade in 2 cohorts of pts with recurrent glioblastoma: nature.com/articles/s43018-0… #BTSM
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Our paper in @Nature demonstrates diverse alterations leading to resistance to G12C inhibition. We must continue to work to advance treatments on behalf of our patients with KRAS mutant cancers nature.com/articles/s41586-0…
JAX Clinical Knowledgebase (JAX-CKB) retweeted
📢Open access article free for all to read on latest in 👉Precision therapy for RET-altered cancers with RET inhibitors 🧬🧪🎯🫁 #PrecisionMedicine #LCSM @trendscancer @CellPressNews @OncoAlert Updates on resistance, CNS, & new drugs in development cell.com/trends/cancer/fullt…
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Out today @Nature! Human tissues accumulate cancer-driver mutations with age, yet tumor formation remains rare, why!? We show that mutant clones in the normal epithelium can have a tumor-protective role by outcompeting and eliminating nascent tumors. nature.com/articles/s41586-0…
JAX Clinical Knowledgebase (JAX-CKB) retweeted
From the September issue: Determinants of Response and Intrinsic Resistance to PD-1 Blockade in #MicrosatelliteInstability-High Gastric Cancer by @JeeyunM @KlempnerSam and colleagues. bit.ly/3zFyooG.
#SamsungMedicalCenter #Immunotherapy
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Mobocertinib now approved for EGFR exon 20 insertions after platinum-based chemotherapy. Great to have more options for our patients! @DFEGFRcenter
onclive.com/view/fda-approve…
JAX Clinical Knowledgebase (JAX-CKB) retweeted
.@US_FDA Approves Dostarlimab-gxly for dMMR Recurrent or Advanced Solid Tumors #oncology ow.ly/yTP450FSXUm
JAX Clinical Knowledgebase (JAX-CKB) retweeted
From bench to bedside: Single-cell analysis for cancer immunotherapy dlvr.it/S5mld2
JAX Clinical Knowledgebase (JAX-CKB) retweeted
Combination ivosidenib/azacitidine has yielded notable improvements in survival over ivosidenib alone in IDH1-positive treatment-naïve acute myeloid leukemia. #leusm
cancernetwork.com/view/phase…